Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial

NCT01003496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2022-03-09

No results posted yet for this study

Summary

The purpose of this 2 year study is to conduct a fully powered effectiveness trial comparing recovery trajectories of 200 drug dependent adults (the subjects) who will be randomly assigned to Treatment as Usual (TAU) or TAU + Long-Term Recovery Management (LTRM).

Conditions

  • Drug Addiction

Interventions

BEHAVIORAL

Treatment as Usual (TAU)

Outpatient substance abuse treatment

BEHAVIORAL

TAU + Long-Term Recovery Management

Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • Maryhaven

    collaborator UNKNOWN
  • University of Arkansas

    collaborator OTHER
  • Wright State University

    lead OTHER

Principal Investigators

  • Robert G Carlson, Ph.D. · Wright State University Boonshoft School of Medicine

  • Russel Falck, MA · Wright State University Boonshoft School of Medicine

  • Gregory Brigham, Ph.D. · Maryhaven

  • Brenda M Booth, Ph.D. · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-05
Primary Completion
2011-07-27
Completion
2011-07-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01003496 on ClinicalTrials.gov